ArchPoint Investors’s Novartis NVS Stock Holding History

ArchPoint Investors’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-3,285	Closed	-$269K	–	110
2021 Q3	$269K	Buy	+3,285	New	+$296K	0.08%	80

Other funds holding NVS

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ArchPoint Investors's NVS Position: Q4 2021 in Review

ArchPoint Investors sold out of Novartis (NVS) in Q4 2021, closing a stake of 3,285 shares — an estimated $269K sold.

ArchPoint Investors first reported a position in NVS in Q3 2021 and held it in 1 quarter. The position peaked at $269K in Q3 2021. 1,146 funds tracked by Wall St. Rank hold NVS as of Q4 2021.

ArchPoint Investors reported no remaining Novartis position as of Q4 2021 after selling out during the quarter.
ArchPoint Investors sold 3,285 Novartis shares in Q4 2021, an estimated $269K.
ArchPoint Investors first reported a position in Novartis in Q3 2021 and held it in 1 quarter.
ArchPoint Investors's Novartis position peaked at $269K in Q3 2021.
1,146 funds tracked by Wall St. Rank held Novartis as of Q4 2021.

Based on ArchPoint Investors's 13F filing for Q4 2021, filed 11 Feb 2022.